ZTEK News & Events

Zentek announces that its wholly-owned subsidiary, Triera Biosciences, plans to begin offering contract research organization, CRO, services for custom aptamer discovery, biosensor enablement, and machine-learning classification support to pharmaceutical, biotechnology, and diagnostics organizations in Canada, the United States, Europe, and other markets that require high-performance molecular recognition tools but do not have in-house SELEX expertise, biosensor engineering capability, or ML classification systems to develop them.

Zentek announces that the Ontario Superior Court of Justice has issued its Reasons for Judgment dated March 12, 2026, in the companion actions Eveleigh et al. v. Zenyatta; Zentek v. Eveleigh et al., 2026 ONSC 1510. The litigation arose following the removal of Aubrey Eveleigh, the Company's founder and former President and CEO, by shareholders at a special meeting held on May 11, 2018. The two companion actions were tried together before Justice Osborne of the Ontario Superior Court of Justice. The Court dismissed substantially all claims advanced by Mr. Eveleigh and his consulting firm, Eveleigh Geological Consulting Inc. Original claims, as filed, exceeded $6 million. At trial, the claims were refined and the Court denied all remaining monetary claims, specifically: A Success Fee claim of $282,500 - denied on the basis that the pre-feasibility study required to trigger the payment obligation was never commenced; Severance claims totaling $1,350,000 under the President's Agreement and related Memorandum of Agreement - found to be void and unenforceable as a result of breaches of fiduciary duty; Unpaid wages of $51,748.82 - denied; Defamation damages of $75,000 - denied, with the Court finding the relevant statements were factually accurate; and Indemnification claims of approximately $194,000 in costs and disbursements - denied. With respect to Zentek's claim for cancellation of 4.5 million founder shares and disgorgement of profits, the Court found that the shares had been properly issued and that there was no basis to set aside the issuance.

Zentek announced the initiation of a pilot evaluation program with Quality Filters to assess the integration of Zentek's proprietary air filtration media technology into Quality's commercial product lines. The pilot program is expected to span approximately 8 to 12 weeks and is designed to assess product compatibility, manufacturing scalability, and end-product performance under real-world commercial conditions. During the pilot period, the teams will collaborate on defining the commercial and technical framework for a potential long-term supply arrangement. This initiative advances Zentek's strategy of following its principal commercialization pathways as outlined in the Company's Management Discussion and Analysis dated February 17, 2026, which focuses on integrating intellectual property into existing filtration products and leveraging existing infrastructure through partnerships with established manufacturers. The Company believes the pilot with Quality represents the first material step toward validating these pathways in the U.S. air filtration market and represents a repeatable, partnership-led commercialization model that can be leveraged in other markets as well.

Zentek's wholly-owned subsidiary, Albany Graphite received final results indicating that its ultra-high purity Albany graphite meets the threshold for applications in a range of high-return markets, including: nuclear energy; defense and national security infrastructure; advanced aerospace and hypersonics; and premium lithium-ion batteries. This follows on previous press releases which confirmed that Albany graphite achieved five-nines purity with an equivalent boron concentration of 2.60 ppm, meeting the less-than-3-ppm threshold generally referenced for nuclear applications. The latest independent testing of Albany graphite bricks represents the culmination of the current stage of AGC's nuclear suitability program and further validate Albany's broader ultra-high-purity performance. In practical terms, these results re-affirm that the unique Albany graphite material can perform to the same demanding standards as the specialized graphite blocks used in advanced nuclear reactors and other critical systems, a capability historically possessed by synthetic graphite supplied almost entirely from foreign states. Independent market research estimates that the global ultra-high-purity graphite market is expected to grow at a compound annual growth rate of about 10.5% through 2030, driven by lithium-ion batteries, semiconductors, advanced nuclear reactors and high-temperature aerospace components. Independent market and policy work further indicates that purified natural graphite is the fastest-growing part of the natural graphite segment, as advances in purification and processing now routinely bring impurities down into the tens of mg/kg range and enable natural graphite to compete in applications that historically depended on synthetic graphite, while policymakers increasingly favour lower-carbon, non-foreign supply in response to ESG and critical-minerals initiatives in North America and Europe. Management of the Company believes that the unique Albany material has the potential to target high-value specialized niches where purified natural material can substitute for synthetic graphite, particularly in nuclear-grade applications, premium lithium-ion battery anodes and specialty high-temperature components, markets which together are expected to require on the order of 100,000-200,000 tonnes per year of purified natural high-purity graphite over the next 15-20 years. Management believes this positions Albany to become a premier Canadian supplier of purified natural ultra-high-purity graphite into these specialty markets. This will decrease Canada's reliance on foreign sources and enhance Canada's security of supply in areas critical to our national defence as well as key strategic sectors.